Lead program investigating MT-601 in patients with refractory lymphomas, including anti-CD19 CAR-T cell therapy, demonstrated safety and efficacy in 9 patients with 78% having objective responses, inc ...

Cells of the innate system respond rapidly to molecular patterns shared by a broad array of pathogens. Meanwhile, the adaptive system, consisting of T and B cells, responds more slowly, targeting ...

Triple-negative breast cancer, an aggressive type of breast cancer, accounts for 10% of all breast cancer cases in the United ...

Results showed Orca’s treatment, a purified mix of donor-derived T cells and stem cells, was safer than standard transplant ...

Coya Therapeutics (COYA) provided a status update of its investigational regulatory T cell-derived exosome platform intended for the treatment ...

On Monday, Brookline Capital Markets initiated coverage on Marker Therapeutics (NASDAQ:MRKR), a company focused on developing T cell-based immunotherapies for cancer, with a Buy rating and a 12-to ...

Marker Therapeutics (NASDAQ:MRKR – Get Free Report) is expected to announce its earnings results before the market opens on ...

T-cell lymphoma is a type of non-Hodgkin lymphoma ... also run tests to identify specific genetic mutations or molecular markers to further characterize the lymphoma and guide treatment decisions.

Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological ...